|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
90,630,000 |
Market
Cap: |
14.94(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$129.52 - $244.6 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 664 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
100,397 |
100,397 |
5,364,251 |
5,588,274 |
Total Sell Value |
$15,909,372 |
$15,909,372 |
$1,039,781,980 |
$1,085,894,829 |
Total People Sold |
2 |
2 |
8 |
9 |
Total Sell Transactions |
6 |
6 |
20 |
54 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Amgen Inc |
10% Owner |
|
2020-12-16 |
4 |
A |
$248.26 |
$21,244,456 |
D/D |
85,573 |
18,677,887 |
|
- |
|
Wang Xiaodong |
Chair, Scientific Advisory Brd |
|
2020-12-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
165,295 |
5,703,162 |
|
- |
|
Amgen Inc |
10% Owner |
|
2020-12-15 |
4 |
A |
$239.31 |
$16,258,723 |
D/D |
67,941 |
18,592,314 |
|
- |
|
Liang Howard |
CFO & Chief Strategy Officer |
|
2020-12-14 |
4 |
S |
$225.24 |
$21,048,454 |
D/D |
(91,900) |
0 |
|
-42% |
|
Liang Howard |
CFO & Chief Strategy Officer |
|
2020-12-14 |
4 |
OE |
$6.50 |
$597,350 |
D/D |
91,900 |
91,900 |
|
- |
|
Liang Howard |
CFO & Chief Strategy Officer |
|
2020-12-14 |
4 |
OE |
$0.50 |
$702,650 |
D/D |
1,405,300 |
1,573,715 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2020-12-11 |
4 |
GA |
$0.00 |
$0 |
I/I |
545,597 |
545,597 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2020-12-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,136,914 |
6,790,656 |
|
- |
|
Wang Xiaodong |
Chair, Scientific Advisory Brd |
|
2020-12-10 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,244,542 |
1,244,542 |
|
- |
|
Wang Xiaodong |
Chair, Scientific Advisory Brd |
|
2020-12-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,332,552 |
5,868,457 |
|
- |
|
Glazer Donald W. |
Director |
|
2020-12-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
589,849 |
2,907,829 |
|
- |
|
Huang Jane |
CMO, Hematology |
|
2020-11-30 |
4 |
AS |
$256.00 |
$401,723 |
D/D |
(1,500) |
0 |
|
15% |
|
Huang Jane |
CMO, Hematology |
|
2020-11-30 |
4 |
OE |
$29.49 |
$44,235 |
D/D |
1,500 |
1,500 |
|
- |
|
Huang Jane |
CMO, Hematology |
|
2020-10-29 |
4 |
AS |
$299.88 |
$450,093 |
D/D |
(1,500) |
0 |
|
7% |
|
Huang Jane |
CMO, Hematology |
|
2020-10-29 |
4 |
OE |
$29.49 |
$44,235 |
D/D |
1,500 |
1,500 |
|
- |
|
Wang Xiaodong |
Chair, Scientific Advisory Brd |
|
2020-10-16 |
4 |
AS |
$320.00 |
$1,600,000 |
I/I |
(5,000) |
0 |
|
1% |
|
Liang Howard |
CFO & Chief Strategy Officer |
|
2020-10-05 |
4 |
AS |
$293.26 |
$4,194,413 |
D/D |
(14,000) |
0 |
|
25% |
|
Liang Howard |
CFO & Chief Strategy Officer |
|
2020-10-05 |
4 |
OE |
$6.50 |
$91,000 |
D/D |
14,000 |
14,000 |
|
- |
|
Wang Xiaodong |
Chair, Scientific Advisory Brd |
|
2020-10-05 |
4 |
AS |
$300.00 |
$1,500,000 |
I/I |
(5,000) |
0 |
|
25% |
|
Wu Xiaobin |
President & GM China |
|
2020-10-05 |
4 |
AS |
$300.00 |
$1,200,000 |
D/D |
(4,000) |
0 |
|
25% |
|
Huang Jane |
CMO, Hematology |
|
2020-09-29 |
4 |
AS |
$274.42 |
$420,568 |
D/D |
(1,500) |
0 |
|
32% |
|
Huang Jane |
CMO, Hematology |
|
2020-09-29 |
4 |
OE |
$29.49 |
$44,235 |
D/D |
1,500 |
1,500 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2020-09-29 |
4 |
AS |
$272.74 |
$6,544,030 |
D/D |
(23,303) |
0 |
|
32% |
|
Oyler John |
Chief Executive Officer |
|
2020-09-28 |
4 |
AS |
$278.50 |
$8,682,063 |
D/D |
(31,000) |
0 |
|
32% |
|
Wang Xiaodong |
Chair, Scientific Advisory Brd |
|
2020-09-25 |
4 |
AS |
$280.29 |
$1,402,116 |
I/I |
(5,000) |
0 |
|
31% |
|
527 Records found
|
|
Page 9 of 22 |
|
|